New Triple-Drug attack shows promise against tough blood cancer
NCT ID NCT07490288
First seen Mar 30, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tests a new three-drug combination (venetoclax, azacitidine, and liposomal mitoxantrone) as the first treatment for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combo can safely improve remission rates. Participants will receive the treatment and then may undergo a stem cell transplant if needed. The trial enrolls 30 people aged 14 and older.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.